Effects of recombinant alpha interferon on chronic active hepatitis B: preliminary results. 1993

Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
Hacettepe University Hospital, School of Medicine, Department of Gastroenterology, Ankara, Turkey.

This paper presents the preliminary results of a study designed to evaluate the effects of alpha interferon in chronic hepatitis B. After six months' treatment with interferon alfa-2b (5 million units (MU), three times weekly) 15 of 25 (60%) patients achieved seroconversion of hepatitis B e antigen, 17 (68%) normalised alanine aminotransferase (ALT) activity, and 15 (60%) showed a decrease in the inflammatory reaction on liver histology. No seroconversions occurred in the control group (n = 10), and none of the control patients achieved a normal ALT or showed a reduction in the inflammatory reaction. Adverse effects were experienced by most patients who received interferon but none warranted stopping the treatment.

UI MeSH Term Description Entries
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
June 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
July 1989, Journal of chemotherapy (Florence, Italy),
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
November 1993, Journal of hepatology,
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
February 1990, Australian and New Zealand journal of medicine,
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
January 1991, Therapia Hungarica (English edition),
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
January 1989, Revista do Hospital das Clinicas,
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
February 1995, Journal of chemotherapy (Florence, Italy),
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
September 1992, Journal of hepatology,
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
February 1995, Transplantation proceedings,
Y Bayraktar, and B Uzunalimoglu, and S Arslan, and T Koseoglu, and B Kayhan, and H Telatar
January 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!